Modeling and Simulation - PK/PD Archives | 第 6 页，共 50 页 | Certara

Blog

通过模型引导的药物开发促进药物公平：ASCPT 2026 见解

Explore how model-informed drug development and AI are advancing pharmacoequity and shaping the future of…

Certara2026 年 3 月 11 日

网络研讨会

Phoenix 8.8 有哪些新功能？

Danielle Pillsbury2026 年 3 月 9 日

Webinar

Modeling Platinum-Induced Nephrotoxicity: A PK/TD Analysis of Calbindin and B2-Microglobulin Urinary Biomarkers

Certara2026 年 3 月 9 日

Guide

Navigate GxP Compliance in the Cloud with Confidence

Master SaaS GxP compliance with risk-based computer system validation (CSV) aligned to GAMP 5, FDA,…

Certara2026 年 3 月 6 日

Blog Knowledge Base

Understanding and calculating steady state pharmacokinetics

Steady state pharmacokinetics can seem abstract and confusing. Read this blog to gain a better…

Certara2026 年 3 月 5 日

Publication

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

This study used model-based meta-analysis (MBMA) to assess how well objective response rate (ORR) predicts…

Danielle Pillsbury2026 年 3 月 4 日

Blog

ADC 首次人体（FIH）剂量选择：成功设计 FIH 研究的关键

Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…

Certara2026 年 3 月 3 日

Live Events

Phoenix Roadshow 2026 – 英国剑桥

Certara2026 年 3 月 2 日

Blog

拥抱模型引导的药物发现：通往更佳临床疗效之路

We cover the evidence of biosimulation improving clinical success rates, making the case for model-informed…

Certara2026 年 2 月 27 日

On-Demand Webinar

Formulate Faster: A Purpose-Built Toolkit for Bioequivalence (Phoenix IVIVC Toolkit)

This webinar introduces the Phoenix IVIVC Toolkit, showing how to perform BE analysis and build…

Certara2026 年 2 月 27 日

© 2026 Certara. 保留所有权力。 | 法律 | 隐私政策

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software